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Abstract
Metabolomics has been applied to diagnose diseases, predict disease progression, and design therapeutic strategies in various
areas of medicine. However, it remains to be applied to the ocular surface diseases, where biological samples are often of limited
quantities. We successfully performed proof-of-concept metabolomics assessment of volume-limited cytology samples from a
clinical form of chronic inflammatory cicatrizing conjunctivitis, i.e., ocular MMP and discovered metabolic changes of signaling
lipid mediators upon disease onset and progression. The metabolomics assessment revealed active oxylipins, lysophospholipids,
fatty acids, and endocannabinoids alterations, fromwhich potential biomarkers linked to inflammatory processes were identified.
Possible underlying mechanisms such as dysregulated enzyme activities (e.g., lipoxygenases, cytochrome P450, and phospho-
lipases) were suggested which may be considered as potential therapeutic targets in future studies.
Key messages
& Metabolic profile of the ocular surface can be measured using impression cytology samples.
& Metabolomics analysis of ocular pemphigoid is presented for the first time.
& The metabolomics assessment of OCP patients revealed active oxylipins, lysophospholipids, fatty acids, and
endocannabinoids alterations.
& Several oxylipins are identified as diagnostic biomarkers for OCP.
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Introduction
Chronic cicatrizing conjunctivitis (CCC) include 35 immuno-
logical and neoplastic entities which lead to ocular surface
scarring, often causing ocular surface dysfunction and loss
of visual ability [1]. Ocular mucous membrane pemphigoid
(MMP) is the most common form of CCC and the high risk
among the causes of blindness in western countries [2]. MMP
is an autoimmune chronic inflammatory mucous disease char-
acterized by subepithelial blistering, with an estimated inci-
dence between 1:12000 and 1:60000 [3]. The ocular surface
has the second highest approximate frequency of involve-
ment, namely, circa 70% of cases [4]. A substantial proportion
of cases, i.e., 27%, has ocular-only disease without any other
mucous involvement [5]. The late diagnosis, which typically
occurs once severe symptoms arise and only in advanced
stages of fibrotic disease, limits the use of adequate treatments
and positive outcomes [6, 7]. According to the MMP
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consensus conference in 2002 [4], the diagnostic confirmation
of clinical suspicion requires direct immunofluorescence
(DIF) on mucosal biopsies, demonstrating linear deposit of
IgG/IgM/IgA/Complement fraction 3 at basement membrane.
However, this diagnostic procedure shows low sensitivity, i.e.,
approximately 50–70% regardless of the site of biopsy [8, 9],
leading to frequent false-negative results [5]. The necessity of
DIF positivity for diagnostic confirmation is controversial but
patients have similar outcome measures when the DIF is neg-
ative; furthermore, patients with ocular-only disease tend to
have more negative results [5, 10].
This lack of diagnostic sensitivity critically affects a
prompt and efficient medical intervention. Furthermore,
a more objective method to identify both inflammatory
and scarring activities to follow up the effects of thera-
py and ultimately guide treatment protocols remains
strongly needed [1].
Immunometabolism is an emerging field in biomedicine
that explores the crosstalk between inflammatory processes
and metabolic signaling. Metabolic profiling is increasing-
ly used to find novel disease biomarkers that inform on
disease activity and therapeutic outcomes [11, 12], and
provide insights into phenotypical variations between indi-
vidual cells [13, 14]. The importance of metabolic and
immunometabolic processes in ocular surface diseases
has been increasingly reported [15–17]. In OCP patients,
levels of tear matrix metalloproteinases (MMPs) and
myeloperoxidase (MPO) are proved significantly elevated,
and tissue inhibitor of metalloproteinase-1 (TIMP-1) de-
creased [18]; the novel technique of LC–MS/MS has been
applied to detect cortisol to cortisone ratio in human ocular
bio-fluids [19], and ocular surface impression cytology
was used to determine the role of neutrophils as a biomark-
er of disease activity and progression [20]. Considering the
inflammatory nature of ocular MMP, it is reasonable to
assume that inflammatory metabolites may be actively in-
volved, which justifies the use of a metabolomics-based
approach to elucidate their roles in the onset and progres-
sion of ocular MMP. More specifically, signaling lipid me-
diators are bioactive lipids and lipid derivatives that medi-
ate a variety of biological signaling events including pro-
inflammatory, anti-inflammatory, or pro-resolving
[21–23]. Metabolomics-based approaches targeting signal-
ing lipid mediators are expected to significantly contribute
to revealing inflammatory processes related to ocular
MMP as well as potential disease biomarkers.
In the present study, we investigated whether a
targeted metabolomics-based approach targeting signal-
ing lipid mediators harvested by non-invasive conjuncti-
val impression cytology could serve as sensitive and ob-
jective diagnostic biomarkers of active chronic inflamma-




We conducted an observational case-control pilot study of all
new consecutive patients with diagnosis of ocular MMP who
visited the Cornea service (Rome, Italy) from October to
December 2017. Patients undergoing conjunctival biopsies
older than 18 years with clinical signs of ocular MMP and
who showed lymph-monocyte inflammatory cells at conjunc-
tival histology were included in the study.
Enrolled subjects were further classified according to the
Tauber-Foster clinical staging system [24], i.e., stage I, chron-
ic conjunctivitis with subepithelial fibrosis; stage II, fornix
restriction; stage III, symblepharon; and stage IV,
ankyloblepharon. Stages II and III were subsequently grouped
in four levels according scarring severity: a (< 25%), b (25–
50%), c (50–75%), and d (> 75%). Patients with other ocular
and/or associated systemic diseases or with modification of
actual treatment within 3 months from the screening visit were
excluded. Age- and sex-matched healthy volunteers, older
than 18 years, with any family or personal history of ocular
surface disease were recruited as control group.
All subjects received complete ocular clinical assessment
with total symptom score (TSyS 0–24) and total sign score
(TSS 0–30) calculated by the sum of each symptom and sign
of the disease. Validated Ocular Surface Disease Index
(OSDI) questionnaires were then used [25] (Table 1).
All experimental procedures used in this study adhered to
the tenets of the declaration of Helsinki concerning human
subjects. The procedures performed were reviewed and ap-
proved by the Intramural Ethical Committee (University
Campus Bio-Medico, Rome, Italy). All participants provided
written informed consent for clinical and laboratory analysis.
Impression cytology samples collection, shipment,
and storage
After topical anesthesia with 0.04% oxybropocaine eye drops,
two imprints (impression cytology, ICs) from each bulbar
conjunctiva, specifically the inferior and temporal conjuncti-
va, were sampled using a Millipore membrane filter (0.22-μm
membrane, Millipore, Milan, Italy). ICs were readily fixed by
using a spray citofix (Bio-Fix Spray, Bio-Optica, Milan, Italy)
according to a standardized procedure [26]. Conjunctival
specimens of 32 Citofix samples were stored at − 80 °C until
further analysis.
Conjunctival biopsies and direct immunofluorescence
Conjunctival biopsies were obtained from clinically suspi-
cious ocular MMP patients. Each biopsy conjunctival frag-
ment was included in paraffin and sectioned to provide
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5-μm sections for light/confocal microscopy. The DIF analy-
sis was performed to identify the presence of a linear immu-
noglobulin deposition alongside the basement membrane
zone (BMZ), according to the specific immunoreactivity
(FC-coupled IgGAM antibodies, OBT0119F, Oxford
Biotech., Oxford, UK), univocally present in ocular cicatricial
pemphigoid positive sections. The basal histology included
Giemsa (48900, Fluka, Milan, Italy), hematoxylin and eosin
(HE, 05-M06014/05-M10002, Bio-Optica, Milan, Italy), and
the periodic acid Schiff (PAS, 04-130802/05-M06002, Bio-
Optica, Milan, Italy) stainings.
Metabolic profiling using ultra-high performance
liquid chromatography–mass spectrometry
The Citofix paper filters of collected samples were cut with a
sterile scalpel and added to 200 μL of an ice-cold mixture
composed of 80% methanol in water (v/v) to lyse cells, which
were subsequently fixed on the filter prior to ultra-high per-
formance liquid chromatography–mass spectrometry
(UHPLC-MS/MS) analysis.
The sample preparation and UHPLC-MS/MS analysis were
performed according to a validated profiling analytical platform
[27, 28] with minor optimization. Briefly, samples were prepared
using liquid-liquid extraction with a mixture of BuOH:MTBE
(1:1, v/v). After evaporation of the supernatant, the dry residues
were reconstituted in amixture ofMeOH:ACN (7:3, v/v) prior to
UHPLC-MS/MS analysis. The developed and validated
UHPLC-MS/MS method targeting different metabolic classes
includes oxylipins, oxidative stress markers, endocannabinoids,
and bile acids. Specifically, target metabolites include
lysophospholipids (LPLs) such as lysophosphatidic acids
(LPAs) , lysophosphat idylethanolamines (LPEs) ,
lysophosphatidylglycerols (LPGs), lysophosphatidylinositols
(LPIs), and lysophosphatidylserines (LPSs); lipids from the
sphinganine and sphingosine classes and their phosphorylated
form; free fatty acids with a carbon chain length from C14 to
C22; various isoprostane classes together with their respective
prostaglandin isomers from different polyunsaturated fatty acids;
oxylipins such as leukotrienes, thromboxanes, and
hydroxyeicosatetraenoic acids; and endocannabinoids such as
anandamide (AEA) and 1-arachidonoyl glycerol/2-
arachidonoyl glycerol (1-AG/2-AG). The signaling lipid media-
tors were analyzed at two different mobile phase pH, namely,
fatty acids, LPLs, sphingolipids, and taurine-conjugated bile
acids at high pH and remaining metabolites at low pH, respec-
tively. Low pH analyses were performed by a Shimadzu LCMS-
8060 system (Shimadzu, Japan) using an Acquity BEH C18
column (50 × 2.1 mm, 1.7 μm; Waters, USA). The mobile
phases were composed of water and 0.1% acetic acid (A); a
mixture of ACN–MeOH (9:1, v/v) and 0.1% acetic acid (B);
and IPAwith 0.1% acetic acid (C). Separations were performed
at 40 °C at a flow rate of 0.7 mL/min using the following gradi-
ent: 20% B and 1% C as starting conditions; changing to 85% B
between 0.75 and 14 min and to 15%C between 11 and 14 min;
conditions held for 0.5min prior to column re-equilibration at the
starting conditions from 14.8 to 16 min. High pH analyses were
performed by a Shimadzu LCMS-8050 system (Shimadzu,
Japan) using a Kinetex® Core-Shell EVO 100 Å C18 column
(50 × 2.1 mm, 1.8 μm; Phemomenex, USA). The mobile phases
consisted of aqueous phase A (95% water and 5% ACN with
2 mM ammonium acetate and 0.1% ammonium hydroxide) and
organic phase B (95% ACN and 5% water with 2 mM ammo-
nium acetate and 0.1% ammonium hydroxide). Separations were
performed at 40 °C at a flow rate of 0.6 mL/min and with the
following gradient: 1% B as starting conditions; increasing to
100% B from 0.7 to 7.7 min; 100% B hold for 0.75 min prior
to re-equilibration at the starting conditions between 8.75 and
11 min. MS/MS acquisition was performed in both electrospray
ionization positive and negative mode using multiple reaction
monitoring (MRM) with polarity switching.
Data pre-processing
Peak integration was performed using LabSolutions
(Shimadzu, Version 5.65). For all metabolites, the peak area
Table 1 Demographic and clinical characteristic of ocular MMP patients
Case Age Sex Biopsy T&F R T&FL Tsys R Tsys L TSS R TSS L OSDI
1 71 F Positive* IIB IIB 15 13 8 6 40
2 48 F Positive IIB IIIA IIB IIIA 9 27 5 5 70
3 65 F Positive IIC IIB 14 14 12 10 68
4 65 M Positive I I 13 12 6 4 40
5 34 M Positive IIA IIB 7 7 7 6 40
6 68 F Positive IIB IIIB IIB IIIB 7 10 12 12 69
7 82 M Positive IIC IIIC IIB IIIC 11 13 8 7 50
8 74 F Positive IIB IIIC IIB IIIB 12 11 8 4 25
T&F, Tauber and Foster classification; R, right eye; L, left eye; Tsys, total symptoms score; TSS, total sign score; OSDI, Ocular Surface Disease Index
questionnaire; T.T., topical therapy; Positive: lymphoplasmacellular infiltrates; Positive*, lymphoplasmacellular infiltrates and DIF positivity
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was corrected using internal standards, by calculating the ratio
of peak area of the target compound to the peak area of the
assigned internal standard to obtain relative quantitation for
each metabolite. Acquired peak area ratios of each metabolite
were performed with statistical analysis using IBM SPSS
Statistics (Version 25.0) and GraphPad Prism (Version 7.0).
Data analysis
All patients’ scores for all outcome variables were calculated
for both eyes, with 95% confidence interval for each outcome
measure. The differences between mean values for the differ-
ent time points were assessedwith one-wayANOVAnonpara-
metric test, and the differences between mean values between
control and patient groups were assessed with independent
nonparametric test. A p value of 0.05 was chosen as the limit
for statistical significance.
Comparative analyses were performed using peak area ra-
tios of each metabolite to (1) stratify metabolic differences
between controls and ocular MMP patients, (2) identify po-
tential signaling lipid mediators as diagnostic biomarker can-
didate, and (3) analyze metabolite dynamics associated with
ocular MMP progression. For all comparative analyses, a p




Eight patients with clinical manifestation and histological di-
agnosis of ocular MMP (34–82 years; mean age 63.4; M/F =
1) were enrolled in an observational case-control pilot study.
Eight healthy volunteers (40–88 years; mean age 71; M/F =
1), undergoing routine age-related cataract surgery, were in-
cluded in the control group. Table 1 lists the clinical features
and demographics of included patients. Only 12.5% of recruit-
ed patients showed positive DIF after conjunctival biopsy
(Fig. 1).
Targeted metabolomics of controls and ocular MMP
patients
Numerous significant differences in the targeted signaling lip-
id mediators assessed using UHPLC-MS/MS in conjunctival
biopsies were observed in MMP patients compared with the
control group. Figures 2 (oxylipins), 3 (lysophospholipids and
fatty acids), and 4 (endocannabinoids) illustrate the metabolite
differences observed between the two groups. Overall, 16
oxylipins (i.e., five metabolites derived from the lipoxygenase
[LOX] pathway, seven derived from the CYP450 pathway,
and four metabolites associated to oxidative stress), six
lysophosphatidic acids (i.e., three LPAs and three cyclic
LPAs [cLPAs]), 10 lysophosphatidyl-derived lipids (i.e., three
LPEs, two LPGs, two LPIs, and three LPSs), seven free fatty
acids, and 10 endocannabinoids showed significantly altered
levels between healthy controls and ocular MMP patients. To
be specific, oxylipins showed accumulated levels in conjunc-
tival biopsies of ocular MMP patients compared with healthy
controls. Moreover, LPA (18:0), cLPA (16:1), cLPA (18:0),
cLPA (18:1), LPE (16:0), LPE (18:0), LPG (16:0), LPG
(18:0), LPI (16:0), LPI (18:0), LPS (16:0), LPS (18:0), and
LPS (18:1) were detected at significantly reduced levels in the
ocular MMP patient group while LPA (20:3), LPA (22:6), and
LPE (22:4) were found at significantly higher levels in the
ocular MMP group. In the free fatty acid class, only oleic acid
(18:1,ω-9) was more abundant in the patient group while the
other targeted polyunsaturated fatty acids were all detected at
lower levels in the patient group. Finally, the detected
endocannabinoids showed lowered levels in ocular MMP pa-
tients, except for 2-arachidonyl glyceryl ether (2-AGE) which
was more abundant in the patient group.
Signaling lipid mediators as potential biomarker
candidates for ocular MMP diagnosis
Among the signaling lipid mediators detected, two metabo-
lites, i.e., 9(S)-HOTrE and (± )5-HEPE, may be suggested as
potential biomarker candidates for ocular MMP diagnosis.
Indeed, those two metabolites were exclusively detected,
and at considerable abundance, in all patients’ conjunctival
biopsies analyzed, as illustrated in Fig. 5, while not detected
in control conjunctival biopsies. This suggests that 9(S)-
HOTrE and (±)5-HEPE were both only produced in ocular
MMP patients, which makes them potential specific disease
biomarker candidates.
Fig. 1 Confocal analysis of ocular cicatricial pemphigoid diagnosis by
polyvalent IgG. Direct immune fluorescence IgG/propidium iodide,
merge, × 20
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Signaling lipid mediators as ocular MMP staging
indicators
The comparative analyses performed among ocular MMP pa-
tients highlighted the metabolic dynamic changes associated
with disease progression. Figure 6 shows that the signaling
lipid mediators were significantly elevated in ocular MMP
stage III. Specifically, (±)5-HEPE, 9-HODE, 8(9)-EpETrE,
LPA (20:3), LPE (18:1), LPE (18:2), LPE (22:4), LPE
(22:5), LPE (22:6), LPG (16:1), LPG (22:6), LPI (18:2), LPI
(22:4), LPS (20:4), LPS (22:4), and LPS (22:6) all showed
elevated levels in the stage III compared with stage II ocular
MMP samples. The results showed metabolic changes in con-
junctival cells, which have associations with deteriorative
characteristics at the advanced stage.
Discussion
Ocular MMP is a complex condition easily misdiagnosed in
first stages when it appears as a recurrent chronic conjunctivi-
tis. More than 80% of patients are reported to have a stage III
Tauber-Foster or higher at presentation [6, 7]. The symptoms
can affect quality of life of patients, years before reaching an
accurate diagnosis and thus, the appropriate systemic immu-
nomodulatory therapy (IMT). DIF is the gold standard diag-
nostic test but shows a low diagnostic sensitivity, particularly
in MMP with ocular manifestation alone. Even if IMT is a
successful approach for controlling the clinically significant
ocular surface inflammation, the subclinical fibrotic process
continues in 40–50% of patients [7, 24]. Moreover, little is
known about the relative effectiveness of IMT drugs to slow
down or stop the fibrosis. The disease progression is also
difficult to assess due to the intrinsic limits of the Tauber-
Foster staging system. Recently, fibroblasts from MMP pa-
tients’ conjunctiva have shown to have a pro-fibrotic pheno-
type compared with a healthy population, preserved when
isolated in vitro [29]. Our study aimed to show that
metabolomics-based analysis of ICs samples is a rapid and
non-invasive approach for identification of novel diagnostic
biomarker candidates as well as new potential therapeutic tar-
gets. Indeed, metabolomics could define the biochemical sta-
tus of each sample and the differential expression in signaling
lipid mediators, giving to clinicians new opportunities in di-
agnosis, prognosis, and staging of the disease.
Previously reported evidence suggested the roles of various
signaling lipid mediators in (patho)physiological processes.
For example, lysophospholipids (LPLs), which are minor
structural components of biological membranes, have been
already reported to be important signaling mediators of a wide
range of biological effects as well as markers of specific bio-
logical processes [30–32]. Indeed, LPEs and LPGs are in-
volved in physiological extracellular matrix remodeling [33]
as well as in chronic inflammatory fibrotic disease, such as
idiopathic pulmonary fibrosis, by inducing TGF-β release and
activation [34]. Another example is prostaglandin F2α
(PGF2α), which is specifically elevated during acute inflam-
matory response in several tissues such as airways, uterus,
vessels’ smooth muscle cells, and eye [35].
In this study, a metabolomics-based approach targeting sig-
naling lipid mediators showed a great potential in revealing
immunometabolic changes associated with ocular MMP onset
Fig. 2 Signaling lipid mediators (oxylipins) in control group and ocular
MMP patients. a Oxylipins-LOX pathway. b Oxylipins-CYP450 path-
way. c Oxylipins-ROS pathway. The intensity represents the relative
quantitation of each metabolite
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and progression. As illustrated in Fig. 2, the oxylipins associ-
ated with elevated levels in ocular MMP samples were mostly
issued either from enzymatic pathways such as LOX and
CYP450 or by non-enzymatic auto-oxidation. Oxylipins are
oxidized lipid mediators derived from fatty acids with various
carbon number and double bonds [36]. Omega-3 fatty acids
such as eicosapentaenoic ac id (EPA, 20:5) and
docosahexaenoic acid (DHA, 22:6) and omega-6 fatty acids
such as arachidonic acid (ARA,20:4), linoleic acid (LA, 18:2),
and dihomo-γ-linolenic acid (DGLA, 20:3) have been report-
edwith anti-inflammatory or pro-inflammatory properties [37,
38]. As supported by Figs. 2a and 3f, increased levels of (±)5-
HEPE were detected in the patient group while its precursor
EPAwas found at significantly lower levels. In addition, 8(S)-
HETrE was more abundant in the patient group while the
concentration of its upstream fatty acid DGLA accordingly
Fig. 3 Signaling lipid mediators (lysophospholipids and fatty acids) in
control group and ocular MMP patients. a Lysophosphatidic acids
( LPA s ) a n d c y c l i c - l y s o p h o s p h a t i d i c a c i d s ( c LPA s ) .
b Lysophosphatidylethanolamines (LPEs). c Lysophosphatidylglycerols
(LPGs). d Lysophosphatidylinositol (LPIs). e Lysophosphatidylserines
(LPSs). f Fatty acids. The intensity represents the relative quantitation
of each metabolite
Fig. 4 Signaling lipid mediators (endocannabinoids) in control group and
ocular MMP patients. The intensity represents the relative quantitation of
each metabolite
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decreased. A similar trend was observed in oxylipins issued
from the CYP450 pathway, as shown in Fig. 2b, where
19(20)-EpDPE was present at higher concentrations in patient
samples while its precursor fatty acid DHA was reduced.
Interestingly, the DiHETrE series of lipid mediators (i.e.,
14,15-DiHETrE, 11,12-DiHETrE, 8,9-DiHETrE, and 5,6-
DiHETrE) derived from ARA were less converted through
CYP450 pathway, which may be explained by a shift towards
the more active production of 8,9-EpETrE from the same pre-
cursor ARA. This is supported by the fact that the DiHETrE
series of oxylipins are downstream products of the EpETrE
series, a conversion that might be less active in the patient
group compared with controls. Figure 2c shows five oxylipins
of the HDoHE subclass which were present at significantly
higher levels in conjunctival biopsies of ocular MMP patients,
suggesting a probable overactive peroxidation of DHA to
Fig. 5 Signaling lipid mediators as potential biomarker candidates for
ocular MMP diagnosis: 9(S)-HOTrE and (±)5-HEPE. Data is shown in
absolute concentration (nM) of the metabolite in conjunctival biopsies in
controls and ocular MMP patients, respectively, calculated based on the
calibration curve which is shown in the insert figure
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Fig. 6 Signaling lipid mediators as mid-late-staging indicators. A panel of oxylipins (a) and lysophospholipids (b–f) significantly increased from stage II
to stage III. The intensity represents the relative quantitation of each metabolite
HDoHEs due to excess of reactive oxygen species (ROS). The
occurrence of tissue fibrosis has been suggested to correlate
with the increase of ROS-related oxidative stress [39, 40].
Therefore, we hypothesize that overproduction of HDoHEs,
which may be considered an oxidative stress readout, may
facilitate conjunctivitis and subepithelial fibrosis.
From a clinical diagnosis perspective, the detected metab-
olites with exclusive expression in ocular MMP compared
with the control group show a promising role in assisting
diagnosis. For instance, two oxylipins 9(S)-HOTrE and (±)
5-HEPE were exclusively detected in the patient group with
an average concentration level ~ 0.5 nM in conjunctival biop-
sies. Other potential diagnostic markers could be LPE (22:4)
and LPA (22:6) which were exclusively expressed in the pa-
tient group as well. However, for the latter compounds, no
absolute concentration could be assessed due to the lack of
commercially available reference standards.
The oxylipins (±)5-HEPE, 9-HODE, and 8(9)-EpETrE all
featured an accumulating trend from stage II to stage III where
the symblepharon appears, being potential indicators underly-
ing the metabolic dynamics associated with ocular MMP pro-
gression. (±)5-HEPE and 9-HODE are 5-LOX-mediated lipid
mediators; a pathological activity of 5-LOX may explain their
abnormal surplus associated with MMP staging. This hypoth-
esis is supported by the evidence of age-dependent increase of
5-LOX and oxidative stress [41, 42] as well as excess forma-
tion of cytotoxic mediators due to overactivation of 5-LOX
[43, 44].
LPLs also showed differential concentrations in the patient
versus control groups. Of interest is the observation that satu-
rated and mono-unsaturated LPLs were detected at lower con-
centrations while the polyunsaturated compounds were re-
markably higher in the ocular MMP group. LPLs are break-
down products of membrane phospholipids, a phenomenon
that occurs by losing one of the fatty acid chains (sn-1 or sn-
2) through the action of phospholipase, with a different cleav-
age position depending of the phospholipase. Generally, sn-1
chain is saturated or mono-unsaturated while sn-2 chain is
usually polyunsaturated. Phospholipases A1 (PLA1s) remove
fatty acyl groups from sn-1 position of phospholipids, produc-
ing saturated/mono-unsaturated fatty acids (oleic acid,
palmitic acid, and stearic acid as common sn-1 chains) and
polyunsaturated LPLs. On the other hand, if the cleavage hap-
pens at sn-2 position by phospholipases A2 (PLA2s), polyun-
saturated fatty acid chains are generated (i.e., ARA, DHA,
EPA as common sn-2 chains) together with saturated/mono-
unsaturated lysophospholipids [45]. Therefore, the observed
trends for the detected fatty acids, LPLs, and derived LPAs
(Figs. 3 and 6) could result from hyperactive PLA1s and/or
hypoactive PLA2s in ocular MMP patients and in patients at a
different disease stage. Even though PLA2s have been report-
ed to be overexpressed or overactive in some inflammatory
conditions [45], they seem to have opposite roles in terms of
ocular disease where PLA2s were found to be protective
against pterygium formation, while downregulated expression
of PLA2s has been reported in pterygium tissues compared
with normal conjunctiva [46]. Further investigations are there-
fore needed to elucidate the enzymatic changes in ocular
MMP.
The endocannabinoid system (ECS) is composed of can-
nabinoid receptors, biosynthetic, and degradative enzymes as
well as endocannabinoids. The latter are lipid-based signaling
molecules involved in regulation of physiological and cogni-
tive processes including fertility, pregnancy, pain sensation,
mood, and memory [47]. Particularly, the ability of modulat-
ing inflammation and pain brings endocannabinoids as poten-
tial therapeutic targets [48, 49]. In this study, a panel of
endocannabinoids was detected at significantly lower levels
in ocular MMP (Fig. 4), suggesting a protective role in phys-
iological ocular environment. With gaining momentum in
treating ocular diseases [47], endocannabinoids have been
proposed as therapeutic approaches in glaucoma [50] and ret-
inal disease [51]. However, the potential role of
endocannabinoids in ocular MMP remains largely unex-
plored. Our research revealed for the first time the lower levels
of endocannabinoids detected in ocular MMP compared with
the control group. More interestingly, a remarkable decline of
AEA, PEA, PDEA, and LEAwas observed from ocular MMP
stage I to stage III; all levels were also lower than in the control
group (data now shown). This may suggest that these com-
pounds could contribute to the onset of ocular MMP and the
development of the disease. Altogether, endocannabinoids
may protect against the onset and progression of ocular
MMP, showing their potential for the development of novel
therapeutic strategies for treating ocular MMP.
Conclusions
The present study demonstrates for the first time the power of
metabolomics in conjunctival impression cytology and re-
veals altered levels of signaling lipid mediators associated
with ocular MMP onset and progression. Multiple metabolites
from different classes, i.e., oxylipins, LPLs, fatty acids, and
endocannabinoids, showed significantly different levels in
conjunctival biopsies of ocular MMP patients compared with
healthy controls, which suggests an underlying metabolic
reprogramming occurring in ocular MMP. Probable mecha-
nisms could be the involvement of inflammatory signaling
lipid mediators abundantly produced through overactive
LOX and cytochrome P450 enzymes, or through non-
enzymatic lipid peroxidation, as well as disruption of PLA1s
and PLA2s. On the other hand, endocannabinoid deficiency
may promote the disease onset and development. The specific
presence of 9(S)-HOTrE and (±)5-HEPE in the ocular surface
in MMP patients can be exploited as potential diagnostic
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biomarker candidates. Accumulating oxylipins and LPLs at
mid-late stage of ocular MMP indicate dynamic variations of
conjunctival cell metabolism with aggravating inflammation
underlying the disease progression. Moreover, these findings
could offer better treatment options and provide potential ther-
apeutic targets for future interventions.
Limitations in this study include small sample size and the
lack of further cicatrizing conjunctivitis patients as controls.
Future perspectives include the validation of these findings in
a larger population of ocular MMP patients and patients af-
fected with other challenging eye surface conditions as prima-
ry Sjogren’s syndrome, a topical keratoconjunctivitis, and
Steven-Johnson syndrome. Moreover, a larger selection of
metabolites will be added to the developed UHPLC-MS/MS
method to increase the validity of these results and offer a
broader knowledge of the eye surface at the metabolite level.
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